Patients were randomly assigned ( 1:1 ) by the minimisation method to receive either trabectedin ( 12 mg/m ( 2 ) given via a central venous line over 24 h on day 1 of a 21 day treatment cycle ) or best supportive care , which was adjusted centrally by pathological subtype .